A key issue in the investigation is the allegation that these drug manufacturers have recklessly and unlawfully pushed addictive opioids. Read more
The antitrust litigation arises from a series of reverse payment settlements worth about $300 million. Read more
A Pennsylvania federal judge said last month that he would approve a $512 million settlement between direct purchasers and Teva Pharmaceutical Industries Ltd. and its subsidiaries Cephalon I... Read more
Cephalon Inc. has agreed to pay $1.2 billion to settle a long-running antitrust suit. The company had been accused by the Federal Trade Commission of paying generic-drug makers to hold off o... Read more
Teva Pharmaceutical Industries Ltd. and subsidiaries Cephalon Inc. and Barr Pharmaceuticals Inc. have agreed to pay $512 million to settle with the direct purchasers in pay-for-delay litigat... Read more
Drug maker Cephalon has paid $425 million to the states to settle allegations of off-label marketing of three pharmaceutical products. The settlement resolves allegations that Cephalon marke... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.